Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
1998-04-27
2002-02-19
Eyler, Yvonne (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S324000, C530S399000, C435S007100, C435S007210, C435S007200, C514S002600
Reexamination Certificate
active
06348573
ABSTRACT:
FIELD OF THE INVENTION
The invention generally relates to compositions and methods for identifying apoptosis signaling pathway inhibitors and activators.
BACKGROUND OF THE INVENTION
Most cells in the body die through a non-inflammatory, energy-dependent form of cell death called apoptosis. Recent research into the molecular mechanisms of apoptosis has revealed that apoptosis is a genetically programmed process that can become deranged when the components of the cellular apoptotic machinery are mutated or present in inappropriate quantities. Dysregulation of apoptosis is associated with the pathogenesis of a wide array of diseases; cancer, neurodegeneration, autoimmunity, heart disease, and other disorders. Some diseases associated with increased apoptosis include AIDS, neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, retinitis pigmentosa), aplastic anemia, ischemic injury (e.g., myocardial infarction, stroke, reperfusion injury), and toxin-induced (e.g., alcohol induced) liver disease. Thus, apoptosis is critical not only during development and tissue homeostasis, but also in the pathogenesis of a variety of diseases. Products of genes involved in the regulation and execution of apoptosis are therefore potentially excellent targets for diagnosis and therapeutic intervention in disease processes, and they offer renewed hope for cures and treatments for a wide array of maladies [See Review by Rudin and Thompson,
Ann. Rev. Med
. 48:267-81 (1997)].
To date, various signaling pathways in apoptosis have been elucidated. Significant progress in defining the extracellular signaling mechanisms regulating apoptosis has been made in lymphocytes. B and T cells both express a wide variety of cell surface receptors that can either induce or inhibit apoptosis. The largest related group of these receptors, with at least 12 members, is the tumor necrosis factor (TNF) receptor (TNFR) family. These are characterized by cysteine-rich pseudorepeats in the N-terminal extracellular domains, through which each member binds to one or more of a family of TNF-related proteins. Under various experimental conditions, several of these receptors (including TNFR2, CD40, and CD30) inhibit apoptosis; others (including TNFR1 and Fas) induce apoptosis in lymphocytes.
The death-inducing receptors TNFR1 and Fas share a related intracellular sequence known as the death domain. FADD (Fas associated death domain protein), RIP, and TRADD (TNFR-associated death domain protein), can heterodimerize with the death domains of these receptors. FADD and RIP interact directly with Fas, whereas TRADD appears to bind only TNFR1. Over expression of any of these cytoplasmic proteins induces apoptosis. The TNFR1-TRADD complex forms only when TNFR1 has engaged extracellular TNF, and the complex was recently shown to secondarily bind FADD by heterodimerization of the C-terminal death domains of TRADD and FADD. Mutations in the N-terminal portion of FADD prevented TNFR1 -induced apoptotic signaling. In addition, the TNFR1-TRADD complex was found to interact with TRAF2 in a pathway required for TNFR1-induced NF&kgr;B activation. These findings suggested that TRADD may serve primarily as a linker between TNFR1 and multiple downstream signaling pathways, including FADD-mediated apoptosis. Interestingly, over expression of the death domain of TRADD or RIP alone is sufficient to induce apoptosis, whereas FADD over expression induces apoptosis only if the N-terminal (effector) domain is intact. FADD mutants with altered death domains that are unable to bind Fas are still lethal. Activation of FADD or similar effector proteins may be essential for both TNFR1- and Fas-mediated apoptosis. Recently, FADD has been shown to interact with a novel member of the ICE protease family known as MACH or FLICE. FADD can recruit this protease to the ligand-engaged Fas receptor and promotes the cleavage of the FLICE prodomain, presumably activating the protease. Although such activation may be sufficient to induce apoptosis, Fas may also activate other signaling molecules that contribute to programmed cell death.
Sequential cytological and biochemical changes are associated with the cellular apoptotic process. The cytoplasm condenses, and the endoplasmic reticulum dilates to form vesicles which fuse with the cell membrane, producing characteristic cellular morphology. Changes in the nuclei include the formation of dense crescent shaped aggregates of chromatin, nucleolus fragmentation, and formation of vesicles at or on the nuclear membrane. During apoptosis, endonucleases present in the cell cut the DNA in the linker regions between nucleosomes to release DNA fragments in integer multiples of 180-190 base pairs [J. J. Cohen et al.,
J. Immunol
. 132:38-42 (1984)]. The pattern of cleavage is believed to result from the vulnerability of the linker DNA between the nucleosomes to endonucleases. However, the elucidation of the cellular signaling transduction mechanisms beginning with the apoptosis inducing agent and leading to DNA fragmentation and apoptosis have not been fully determined.
Better understanding and elucidation of various strategic targets in the cellular signaling transduction machinery that leads to DNA fragmentation and apoptosis would provide suitable compounds for modulating cell growth and proliferation by regulation of the apoptotic signaling pathway. What is required are suitable methods and compositions for the identification of compounds that have therapeutic utility where cell growth or proliferation is aberrant, for example, as anti-neoplastic agents.
SUMMARY OF THE INVENTION
The present invention generally relates to compositions and methods for identifying apoptosis signaling pathway inhibitors and activators and more particularly, methods and compositions for screening compounds and identifying compounds that will modulate the interactions of the various compositions identified in the present invention; ARC, RICK and the CIDE family of activators (CIDE-A, CIDE-B, DREP-1) with other members of the signaling pathway, i.e., their substrates or ligands. It is not intended that the present invention be limited to particular cell death signaling pathways. The present invention contemplates that the methods and compositions described herein will be useful with a variety of apoptosis-signaling receptors, to identify compounds that will modulate the interactions of ARC, RICK and the CIDE family of activators with other members of the apoptosis signaling pathway, i.e., their substrates or ligands.
In one embodiment, the present invention contemplates an isolated nucleic acid encoding at least a fragment of the RICK protein(RIP-like interacting CLARP kinase), that functions as a positive regulator of apoptosis, having the amino acid sequence (1-531) set forth in SEQ ID NO:1. It is not intended that the present invention be limited by the size or nature of the fragment. In one embodiment, said nucleic acid encodes full-length RICK as set forth in (SEQ ID NO:1) and said nucleic acid comprises SEQ ID NO:2 are contemplated. In another embodiment, the said RICK protein has a mutation at the ATP-binding site, in which the lysine residue is replaced by methionine at position 38 of the amino acid sequence set forth in SEQ ID NO:3. In another embodiment, said nucleic acid encodes a fragment. It is not intended that the present invention be limited by the nature or size of the fragment. For example, fragements comprising either residues 54-531 (SEQ ID NO:4), residues 248-531(SEQ ID NO:5), or residues 365-531 (SEQ ID NO:6), or residues 1-365 (SEQ ID NO:7) of the amino acid sequence set forth in SEQ ID NO:1. In yet another embodiment, said nucleic acid encodes a fusion protein.
It is not intended that the present invention be limited as to the specific nature of the nucleic acid encoding the peptides described above. In one embodiment, said nucleic acid is contained in a vector. In another embodiment, said vector is in a host cell.
In one embodiment, the present in
Inohara Naohiro
Koseki Takeyoshi
Nunez Gabriel
Andres Janet
Eyler Yvonne
Medlen & Carroll LLP
The Regents of the University of Michigan
LandOfFree
Compositions and methods for identifying apoptosis signaling... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for identifying apoptosis signaling..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for identifying apoptosis signaling... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2978358